Mesoblasts P3 GVHD Trial Completes Enrollment
Filed with ASX · · 2 pages · English
Story so far
Earlier from Mesoblast
- Mesoblast Grants TiGenix License For Treatment of Fistulae
- MSB Named Global Technology Leader In Cell Therapy Industry
- Response to ASX Aware Letter Query
- Mesoblast Provides Corporate Update and Q1 Financial Results
- RA Phase 2 Trial Results Presented At ACR Annual Meeting
Later from Mesoblast
- Mesoblast Receives RMAT For LVAD Heart Failure Patients
- Appendix 3B with prospectus
- Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
- GVHD Day 28 Results Presentation
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast